GILEAD SCIENCES, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff
GILEAD SCIENCES, INC. (GILD) reported Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff of $0 for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff · last filed 2020-08-06
- GILEAD SCIENCES, INC. debt securities, available-for-sale, allowance for credit loss, writeoff for the quarter ending 2020-06-30 was $0.00.
- GILEAD SCIENCES, INC. debt securities, available-for-sale, allowance for credit loss, writeoff for the quarter ending 2020-03-31 was $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff 3 month | Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff 6 month |
|---|---|---|
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |